COMMUNIQUÉS West-GlobeNewswire

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
29/09/2025
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage [...]
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
29/09/2025
Next generation sustained-release formulations for a variety of peptides Executive summary first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for [...]
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
29/09/2025
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
28/09/2025
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company [...]
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
28/09/2025
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher [...]
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
28/09/2025
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a [...]
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
26/09/2025
Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients [...]
Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities
26/09/2025
ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the [...]
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
26/09/2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and [...]
Glucose Health, Inc. Announces Officer Changes Effective September 30, 2025
26/09/2025
BENTONVILLE, Ark., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced that its Chief Executive Officer and Chief Financial Officer has resigned, effective September 30, 2025, for [...]
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
26/09/2025
PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non [...]
Tekton Research Expands Clinical Network with Three New Sites, Five New Investigators, and CNS Thought Leader
26/09/2025
Growth supports Tekton’s strategic focus on CNS and Cardiometabolic research AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Tekton Research, a leading multi-site clinical trial company, is proud to announce the [...]
Shape Therapeutics Announces Multiple Oral Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
26/09/2025
Talks will cover the use of a novel BBB-penetrant, AAV5-derived CNS capsid and development of an RNA-targeting disease-modifying gene therapy, SHP-201, for treatment of Parkinson’s Disease SEATTLE, Sept. 26, 2025 (GLOBE [...]
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
26/09/2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 26 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the [...]
24/7 Market News: Kraig Labs Offers Safer, Natural Alternative to Health Risks from Nylon and Polyester Clothing
26/09/2025
DENVER, Sept. 26, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories’ (OTCQB: [...]
Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025
26/09/2025
September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips d ebuts helium-free [2] BlueSeal RT 1.5T 70cm MR [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
26/09/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 26 September 2025 at 16.30 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
26/09/2025
Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today [...]
Shape Therapeutics Announces Multiple Oral and Poster Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
26/09/2025
Talks will cover the use of a novel BBB-penetrant, AAV5-derived CNS capsid and development of an RNA-targeting disease-modifying gene therapy, SHP-201, for treatment of Parkinson’s Disease SEATTLE, Sept. 26, 2025 (GLOBE [...]

Pages